The Clinical Study of Okra Capsule Combined with Tacrolimus and Glucocorticoid in the Treatment of Nephrotic Syndrome
Objective:To observe and discuss the clinical effect of combined treatment of okra capsule,tacrolimus and glucocorticoid in patients with nephrotic syndrome.Method:From January 2021 to January 2024,80 patients with nephrotic syndrome admitted to the Department of Nephrology of Jingbian County People's Hospital.They were divided into control group(40 cases were treated with tacrolimus combined with glucocorticoid)and observation group(40 cases were treated with tacrolimus combined with glucocorticoid combined with okra capsule)according to the principle of random number table.Total remission efficiency,renal function[urinary microprotein excretion rate(UAER),total urinary protein(UTP),urea nitrogen(BUN),blood creatinine(Scr)],inflammatory oxidation indexes[nitric oxide(NO),malondialdehyde(MDA),heme oxygenase(HO-1),tumor necrosis fact-α(TNF-α)]and adverse reactions were compared.Result:The total remission efficiency of observation group was 95.00%,which was higher than that of control group,and the difference was statistically(P<0.05).Before treatment,there was no significant difference in renal function,inflammation and oxidation indexes between two groups(P>0.05).After treatment,UAER,UTP,BUN,Scr,MDA,HO-1,TNF-α were decreased and NO was increased in both groups,and UAER,UTP,BUN,Scr,MDA,HO-1,TNF-α were lower and NO was higher in observation group than control group(P<0.05).There was no significant difference in adverse reactions between observation group and control group during treatment(P>0.05).Conclusion:The combination of tacrolimus and glucocorticoid therapy in patients with nephrotic syndrome has a significant effect,which can improve renal function,reduce inflammation and oxidation reaction,and has high safety.
国家科技期刊平台
NSTL
万方数据
